Sanofi Consumer Healthcare India Limited has reported a notable total income of ₹6,412 million for the third quarter ending September 30, 2025, marking a significant increase from ₹5,618 million during the same period last year. The company's revenue from operations reached ₹2,339 million, up from ₹1,599 million in Q3 2024, while other income contributed ₹30 million to the total. The Board of Directors approved these unaudited financial results during a meeting held on November 12, 2025, underscoring the company's commitment to transparency and regulatory compliance as outlined in the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Regarding expenses, Sanofi reported a total of ₹1,528 million for the quarter, which is a notable increase from ₹1,017 million in Q3 2024. Key expenses included ₹365 million for materials consumed and ₹317 million in employee benefits. The profit before tax for the quarter was ₹841 million, compared to ₹612 million in the previous year, demonstrating a robust operational performance. The profit after tax for the quarter stood at ₹629 million, reflecting a solid growth trajectory. The increase is attributed in part to the successful relaunch of several products, including Depura Adult and Allegra Suspension, which had previously been recalled as a precautionary measure.

For the nine months ending September 30, 2025, the company reported an overall profit of ₹1,736 million, up from ₹1,367 million during the same timeframe last year, highlighting a continuous growth trend. The basic earnings per share (EPS) for the period was ₹75.38, compared to ₹59.36 in the prior year. Sanofi's management attributes this growth to both enhanced domestic and export sales, with the latter seeing an impressive increase of 1,031% on a low base for Q3, alongside a 20% growth in domestic sales. These results reflect Sanofi's strategic initiatives and operational efficiency in a competitive market landscape.